Ming Hsieh Reports Q4 Revenue of $83.34M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 27 2026
0mins
Should l Buy FLGT?
Reports Q4 revenue $83.34M, consensus $85.38M. Ming Hsieh, chairman and CEO, said, "I am pleased with the progress we made in 2025 as we delivered on our strategic and product innovation roadmap. The laboratory services business sustained momentum, and the business is benefiting from the investments we made in AI and digital pathology solutions. We also accelerated progress on our therapeutic development pipeline in 2025 for both clinical candidates, as FID-007 advanced through Phase 2 and FID-022 is progressing through Phase 1. We expect continued progress this year, and we believe the strategic investments we have made in our technology and capabilities will have a significant impact over the long term as we strive to expand our market reach."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy FLGT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on FLGT
Wall Street analysts forecast FLGT stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 15.560
Low
30.00
Averages
32.50
High
35.00
Current: 15.560
Low
30.00
Averages
32.50
High
35.00
About FLGT
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported lower-than-expected financial results for Q4 and full year 2025 on February 27, 2026, indicating that 2026 guidance reflects the impact of its largest customer moving significant work in-house, leading to decreased investor confidence.
- Stock Price Volatility: Following the earnings report, Fulgent's stock price plummeted from $24.76 on February 26, 2026, to $15.33, marking a 38.1% decline, which reflects market concerns regarding the company's future outlook.
- Legal Investigation Initiated: Kirby McInerney LLP has launched an investigation into potential violations of federal securities laws by Fulgent and its senior management; while no lawsuit has been filed yet, the ongoing investigation could impact the company's reputation and shareholder interests.
- Investor Action Advisory: The law firm advises investors who purchased Fulgent securities or have relevant information to contact them to discuss their rights, highlighting the potential risks associated with the company's legal issues and the strategies investors might consider.
See More
Fulgent Genetics Completes Acquisition of Bako and StrataDx
- Acquisition Completion: Fulgent Genetics has completed the acquisition of Bako Diagnostics and StrataDx for approximately $56.9 million in cash, which is expected to enhance its market position in pathology and dermatopathology, driving future revenue growth.
- Asset Integration Benefits: This acquisition allows Fulgent to integrate Bako's specialized laboratory testing services with StrataDx's advanced dermatopathology offerings, thereby enhancing its technical capabilities and service range, further solidifying its competitive edge in precision medicine.
- Market Expansion Potential: The addition of Bako and StrataDx enables Fulgent to offer a more comprehensive range of pathology services, addressing the growing market demand, particularly in cancer diagnostics and treatment, which is expected to attract more clients and increase market share.
- Strategic Development Direction: This acquisition aligns with Fulgent's strategic goal of transforming into a fully integrated precision medicine company, demonstrating its commitment to achieving long-term growth through technological innovation and market expansion.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Miss: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025, slightly below the previously updated guidance, indicating increased competitive pressure that may undermine investor confidence.
- Quarterly Revenue Decline: The company's fourth-quarter revenue showed a sequential decline, reflecting sluggish business growth that could lead to poor future financial performance and impact shareholder returns.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by Fulgent, and if confirmed, this could result in significant legal and financial repercussions for the company, further affecting its market reputation.
- Investor Losses Attention: The firm is offering legal support for investors who suffered losses in Fulgent securities, highlighting a commitment to protecting investor rights, which may attract more affected investors to participate in potential litigation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Disclosure: Fulgent Genetics reported its 2025 fiscal year revenue at approximately $322.7 million on February 27, 2026, which slightly missed the previously updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company's fourth-quarter revenue showed a sequential decline, reflecting ongoing operational challenges that could impact investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Prominent law firm Lowey Dannenberg is investigating potential violations of federal securities laws by Fulgent, and if confirmed, this could result in significant legal and financial repercussions for the company.
- Investor Losses Attention: The firm encourages investors who suffered losses in Fulgent securities to participate in the investigation, highlighting the market's heightened focus on corporate governance and compliance issues.
See More
Pomerantz Investigates Fulgent Genetics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating Fulgent Genetics for potential securities fraud or unlawful business practices by its officers, which could lead to significant losses for investors.
- Lowered Guidance: On February 27, 2026, Fulgent reported lower-than-expected guidance for 2026, primarily due to its largest customer moving significant work in-house, indicating market pressures on the company.
- Stock Price Plunge: Following the disappointing guidance, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting investor concerns about the company's future outlook.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities litigation firm, may provide legal support to affected investors, potentially exacerbating Fulgent's legal and financial risks.
See More
Fulgent Genetics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Fulgent Genetics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further declines in stock price.
- Poor Financial Performance: Fulgent's financial results released on February 27, 2026, revealed lower-than-expected performance for Q4 and the full year 2025, particularly with disappointing guidance for 2026 due to its largest customer moving significant work in-house.
- Stock Price Plunge: Following this news, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting the market's pessimism regarding the company's future prospects.
- Potential Legal Consequences: Should the investigation confirm misconduct by Fulgent and its executives, the company may face class action lawsuits, further damaging its reputation and impacting future financing capabilities.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Decline: Fulgent Genetics reported lower-than-expected financial results for Q4 and full year 2025 on February 27, 2026, indicating that 2026 guidance reflects the impact of its largest customer moving significant work in-house, leading to decreased investor confidence.
- Stock Price Volatility: Following the earnings report, Fulgent's stock price plummeted from $24.76 on February 26, 2026, to $15.33, marking a 38.1% decline, which reflects market concerns regarding the company's future outlook.
- Legal Investigation Initiated: Kirby McInerney LLP has launched an investigation into potential violations of federal securities laws by Fulgent and its senior management; while no lawsuit has been filed yet, the ongoing investigation could impact the company's reputation and shareholder interests.
- Investor Action Advisory: The law firm advises investors who purchased Fulgent securities or have relevant information to contact them to discuss their rights, highlighting the potential risks associated with the company's legal issues and the strategies investors might consider.
See More
Fulgent Genetics Completes Acquisition of Bako and StrataDx
- Acquisition Completion: Fulgent Genetics has completed the acquisition of Bako Diagnostics and StrataDx for approximately $56.9 million in cash, which is expected to enhance its market position in pathology and dermatopathology, driving future revenue growth.
- Asset Integration Benefits: This acquisition allows Fulgent to integrate Bako's specialized laboratory testing services with StrataDx's advanced dermatopathology offerings, thereby enhancing its technical capabilities and service range, further solidifying its competitive edge in precision medicine.
- Market Expansion Potential: The addition of Bako and StrataDx enables Fulgent to offer a more comprehensive range of pathology services, addressing the growing market demand, particularly in cancer diagnostics and treatment, which is expected to attract more clients and increase market share.
- Strategic Development Direction: This acquisition aligns with Fulgent's strategic goal of transforming into a fully integrated precision medicine company, demonstrating its commitment to achieving long-term growth through technological innovation and market expansion.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Miss: Fulgent Genetics reported approximately $322.7 million in revenue for the full year 2025, slightly below the previously updated guidance, indicating increased competitive pressure that may undermine investor confidence.
- Quarterly Revenue Decline: The company's fourth-quarter revenue showed a sequential decline, reflecting sluggish business growth that could lead to poor future financial performance and impact shareholder returns.
- Legal Investigation Initiated: Lowey Dannenberg P.C. is investigating potential violations of federal securities laws by Fulgent, and if confirmed, this could result in significant legal and financial repercussions for the company, further affecting its market reputation.
- Investor Losses Attention: The firm is offering legal support for investors who suffered losses in Fulgent securities, highlighting a commitment to protecting investor rights, which may attract more affected investors to participate in potential litigation.
See More
Fulgent Genetics Under Investigation for Securities Violations
- Financial Performance Disclosure: Fulgent Genetics reported its 2025 fiscal year revenue at approximately $322.7 million on February 27, 2026, which slightly missed the previously updated guidance, indicating pressure in market competition.
- Quarterly Revenue Decline: The company's fourth-quarter revenue showed a sequential decline, reflecting ongoing operational challenges that could impact investor confidence and lead to stock price volatility.
- Legal Investigation Initiated: Prominent law firm Lowey Dannenberg is investigating potential violations of federal securities laws by Fulgent, and if confirmed, this could result in significant legal and financial repercussions for the company.
- Investor Losses Attention: The firm encourages investors who suffered losses in Fulgent securities to participate in the investigation, highlighting the market's heightened focus on corporate governance and compliance issues.
See More
Pomerantz Investigates Fulgent Genetics for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating Fulgent Genetics for potential securities fraud or unlawful business practices by its officers, which could lead to significant losses for investors.
- Lowered Guidance: On February 27, 2026, Fulgent reported lower-than-expected guidance for 2026, primarily due to its largest customer moving significant work in-house, indicating market pressures on the company.
- Stock Price Plunge: Following the disappointing guidance, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting investor concerns about the company's future outlook.
- Potential Legal Consequences: Pomerantz LLP, a prominent securities litigation firm, may provide legal support to affected investors, potentially exacerbating Fulgent's legal and financial risks.
See More
Fulgent Genetics Under Investigation for Securities Fraud
- Securities Fraud Investigation: Pomerantz LLP is investigating whether Fulgent Genetics has engaged in securities fraud or other unlawful business practices, which could undermine investor confidence and lead to further declines in stock price.
- Poor Financial Performance: Fulgent's financial results released on February 27, 2026, revealed lower-than-expected performance for Q4 and the full year 2025, particularly with disappointing guidance for 2026 due to its largest customer moving significant work in-house.
- Stock Price Plunge: Following this news, Fulgent's stock price fell by $9.43, or 38.09%, closing at $15.33 per share on February 27, 2026, reflecting the market's pessimism regarding the company's future prospects.
- Potential Legal Consequences: Should the investigation confirm misconduct by Fulgent and its executives, the company may face class action lawsuits, further damaging its reputation and impacting future financing capabilities.
See More
